(DCI) Donaldson - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2576511099

Filters, Collectors, Purifiers, Bioprocessing, Membranes

EPS (Earnings per Share)

EPS (Earnings per Share) of DCI over the last years for every Quarter: "2021-01": 0.52, "2021-04": 0.66, "2021-07": 0.66, "2021-10": 0.61, "2022-01": 0.57, "2022-04": 0.67, "2022-07": 0.84, "2022-10": 0.7, "2023-01": 0.75, "2023-04": 0.76, "2023-07": 0.78, "2023-10": 0.75, "2024-01": 0.81, "2024-04": 0.92, "2024-07": 0.94, "2024-10": 0.83, "2025-01": 0.83, "2025-04": 0.99, "2025-07": 1.03, "2025-10": 0.94,

Revenue

Revenue of DCI over the last years for every Quarter: 2021-01: 679.1, 2021-04: 765, 2021-07: 773.1, 2021-10: 760.9, 2022-01: 802.5, 2022-04: 853.2, 2022-07: 890, 2022-10: 847.3, 2023-01: 828.3, 2023-04: 875.7, 2023-07: 879.5, 2023-10: 846.3, 2024-01: 876.7, 2024-04: 927.9, 2024-07: 935.4, 2024-10: 900.1, 2025-01: 870, 2025-04: 940.1, 2025-07: 980.7, 2025-10: 935.4,

Dividends

Dividend Yield 1.27%
Yield on Cost 5y 2.13%
Yield CAGR 5y 7.69%
Payout Consistency 99.5%
Payout Ratio 30.9%
Risk via 5d forecast
Volatility 20.4%
Value at Risk 5%th 31.5%
Relative Tail Risk -6.21%
Reward TTM
Sharpe Ratio 1.24
Alpha 21.63
CAGR/Max DD 0.71
Character TTM
Hurst Exponent 0.274
Beta 0.856
Beta Downside 0.766
Drawdowns 3y
Max DD 23.81%
Mean DD 5.48%
Median DD 4.47%

Description: DCI Donaldson January 06, 2026

Donaldson Company Inc. (NYSE: DCI) designs, manufactures, and distributes filtration systems and replacement parts across three operating segments: Mobile Solutions, Industrial Solutions, and Life Sciences. The Mobile Solutions segment supplies air- and liquid-filtration components-such as fuel, lube, hydraulic, and emissions filters-to OEMs in construction, mining, agriculture, and transportation, as well as to independent distributors and dealer networks. The Industrial Solutions segment covers dust, fume, and mist collectors; compressed-air and gas-purification units; power-generation inlet systems; and aerospace/defense filtration for aircraft, ground-vehicle, and naval platforms. The Life Sciences segment provides micro-environment gas and liquid filtration for food-beverage, bioprocessing (bioreactors, fermenters, chromatography consumables), and high-purity applications in semiconductors, hard-disk drives, battery systems, and powertrain components.

Key performance indicators from the most recent fiscal year (2023) show total revenue of roughly $2.5 billion, an operating margin of ≈ 12 %, and a backlog of about $1.1 billion, indicating solid demand visibility. The company’s growth is tied to macro-drivers such as the global shift toward electric vehicles (which raises demand for high-efficiency coolant and battery filtration), expanding renewable-energy generation (requiring robust air-inlet and gas-purification for turbines), and continued expansion of biopharma manufacturing capacity, which fuels the Life Sciences segment.

Analysts should watch the OEM cycle in the construction and mining sectors-where a slowdown could compress Mobile Solutions sales-and monitor the pace of EV adoption, as higher-volume battery packs increase the need for specialized filtration. Additionally, the aerospace-defense market’s fiscal-year spending trends can materially affect the Industrial Solutions segment’s top line. For a deeper dive into DCI’s valuation metrics, the ValueRay platform offers a concise, data-rich overview.

Piotroski VR‑10 (Strict, 0-10) 8.0

Net Income (381.9m TTM) > 0 and > 6% of Revenue (6% = 223.6m TTM)
FCFTA 0.13 (>2.0%) and ΔFCFTA 2.15pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 21.75% (prev 18.65%; Δ 3.10pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.16 (>3.0%) and CFO 471.3m > Net Income 381.9m (YES >=105%, WARN >=100%)
Net Debt (463.3m) to EBITDA (633.3m) ratio: 0.73 <= 3.0 (WARN <= 3.5)
Current Ratio 2.15 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (117.8m) change vs 12m ago -3.36% (target <= -2.0% for YES)
Gross Margin 34.76% (prev 35.31%; Δ -0.55pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 122.8% (prev 119.6%; Δ 3.17pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 20.74 (EBITDA TTM 633.3m / Interest Expense TTM 25.8m) >= 6 (WARN >= 3)

Altman Z'' 8.18

(A) 0.27 = (Total Current Assets 1.51b - Total Current Liabilities 703.9m) / Total Assets 3.03b
(B) 0.90 = Retained Earnings (Balance) 2.72b / Total Assets 3.03b
warn (B) unusual magnitude: 0.90 — check mapping/units
(C) 0.18 = EBIT TTM 535.0m / Avg Total Assets 3.04b
(D) 2.19 = Book Value of Equity 3.31b / Total Liabilities 1.51b
Total Rating: 8.18 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 86.91

1. Piotroski 8.0pt
2. FCF Yield 3.71%
3. FCF Margin 10.82%
4. Debt/Equity 0.44
5. Debt/Ebitda 0.73
6. ROIC - WACC (= 10.49)%
7. RoE 25.55%
8. Rev. Trend 79.58%
9. EPS Trend 84.97%

What is the price of DCI shares?

As of January 07, 2026, the stock is trading at USD 92.16 with a total of 528,826 shares traded.
Over the past week, the price has changed by +2.07%, over one month by +0.44%, over three months by +11.38% and over the past year by +38.54%.

Is DCI a buy, sell or hold?

Donaldson has received a consensus analysts rating of 3.00. Therefor, it is recommend to hold DCI.
  • Strong Buy: 1
  • Buy: 0
  • Hold: 6
  • Sell: 0
  • Strong Sell: 1

What are the forecasts/targets for the DCI price?

Issuer Target Up/Down from current
Wallstreet Target Price 91.6 -0.6%
Analysts Target Price 91.6 -0.6%
ValueRay Target Price 109.6 19%

DCI Fundamental Data Overview January 05, 2026

Market Cap USD = 10.42b (10.42b USD * 1.0 USD.USD)
P/E Trailing = 28.0156
P/E Forward = 22.3214
P/S = 2.7955
P/B = 6.8391
P/EG = 2.022
Beta = 0.994
Revenue TTM = 3.73b USD
EBIT TTM = 535.0m USD
EBITDA TTM = 633.3m USD
Long Term Debt = 671.5m USD (from longTermDebt, last quarter)
Short Term Debt = 2.50m USD (from shortTermDebt, last quarter)
Debt = 674.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 463.3m USD (from netDebt column, last quarter)
Enterprise Value = 10.88b USD (10.42b + Debt 674.0m - CCE 210.7m)
Interest Coverage Ratio = 20.74 (Ebit TTM 535.0m / Interest Expense TTM 25.8m)
FCF Yield = 3.71% (FCF TTM 403.2m / Enterprise Value 10.88b)
FCF Margin = 10.82% (FCF TTM 403.2m / Revenue TTM 3.73b)
Net Margin = 10.25% (Net Income TTM 381.9m / Revenue TTM 3.73b)
Gross Margin = 34.76% ((Revenue TTM 3.73b - Cost of Revenue TTM 2.43b) / Revenue TTM)
Gross Margin QoQ = 35.15% (prev 34.55%)
Tobins Q-Ratio = 3.59 (Enterprise Value 10.88b / Total Assets 3.03b)
Interest Expense / Debt = 1.05% (Interest Expense 7.10m / Debt 674.0m)
Taxrate = 22.78% (33.6m / 147.5m)
NOPAT = 413.1m (EBIT 535.0m * (1 - 22.78%))
Current Ratio = 2.15 (Total Current Assets 1.51b / Total Current Liabilities 703.9m)
Debt / Equity = 0.44 (Debt 674.0m / totalStockholderEquity, last quarter 1.52b)
Debt / EBITDA = 0.73 (Net Debt 463.3m / EBITDA 633.3m)
Debt / FCF = 1.15 (Net Debt 463.3m / FCF TTM 403.2m)
Total Stockholder Equity = 1.49b (last 4 quarters mean from totalStockholderEquity)
RoA = 12.62% (Net Income 381.9m / Total Assets 3.03b)
RoE = 25.55% (Net Income TTM 381.9m / Total Stockholder Equity 1.49b)
RoCE = 24.70% (EBIT 535.0m / Capital Employed (Equity 1.49b + L.T.Debt 671.5m))
RoIC = 19.15% (NOPAT 413.1m / Invested Capital 2.16b)
WACC = 8.66% (E(10.42b)/V(11.09b) * Re(9.17%) + D(674.0m)/V(11.09b) * Rd(1.05%) * (1-Tc(0.23)))
Discount Rate = 9.17% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.98%
[DCF Debug] Terminal Value 77.81% ; FCFE base≈377.9m ; Y1≈464.5m ; Y5≈785.7m
Fair Price DCF = 94.25 (DCF Value 10.87b / Shares Outstanding 115.3m; 5y FCF grow 24.50% → 3.0% )
EPS Correlation: 84.97 | EPS CAGR: 14.27% | SUE: 0.60 | # QB: 0
Revenue Correlation: 79.58 | Revenue CAGR: 4.17% | SUE: 0.64 | # QB: 0
EPS next Quarter (2026-04-30): EPS=1.06 | Chg30d=+0.012 | Revisions Net=+4 | Analysts=6
EPS current Year (2026-07-31): EPS=4.04 | Chg30d=+0.027 | Revisions Net=+7 | Growth EPS=+9.8% | Growth Revenue=+3.6%
EPS next Year (2027-07-31): EPS=4.42 | Chg30d=+0.062 | Revisions Net=+6 | Growth EPS=+9.4% | Growth Revenue=+4.6%

Additional Sources for DCI Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle